Replies to post #743800 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

New MHRA Assessment Data is out for December 2024. This time it's a positive update with (2) NAS MAA applications reaching determination in 252 clock-on days.

Assuming a 60 day clock-off period, NWBO's NAS MAA is:

297 clock-on days from January 24, 2024 initial validation

254 clock-on days from March 7, 2024 validation confirmation

https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:763c6eb9-4fbf-433f-b18b-f3fee93cd281</span>;

[j e d]

funny how the late-Jan / early-Feb timeline also lines up with the technical charts:

$NWBO Weekly Heinkin Ashi & Candlestick RSI Fancy Action pic.twitter.com/gYc6YYnsJ1

— 3PuttBogey (@3_Putt_Bogey_) January 12, 2025

[LTR]

Do you know if approval is likely to come for these last 3 meds, one at a time, one per week, or can they approve 3 at a time. I know all speculation is useless in the end, but what the hell. What else have we to do while waiting?

[flipper44]

Thank you TVP! I missed your post earlier when I skimmed forward to Stonk’s MHRA performance review update.

I agree.

[beartrap12]

Tunnelvisionofplenty, I looked up one of the two drugs you mentioned were ahead of us for MHRA approval and my google search showed it was approved years ago. I must be missing something. Here is what I found:

AI Overview
Learn more
Illuccix (gallium Ga 68 gozetotide) FDA Approval History ...
The MHRA granted a license for gallium-68 gozetotide, also known as Locametz, in August 2022. This license allows for the use of gallium-68 gozetotide as a radioactive diagnostic agent for prostate cancer in Great Britain.
Explanation
Gallium-68 gozetotide is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to identify prostate cancer lesions.
The MHRA granted a license for gallium-68 gozetotide after the European Medicines Agency (EMA) fully authorized it in December 2022.
The FDA approved gallium-68 gozetotide in December 2021.
The most common side effects of gallium-68 gozetotide are nausea, vomiting, constipation, and tiredness.

Here is what you wrote:
One caveat is that, assuming the other 2 drugs (mRESVIA and gallium-68 gozetotide) were approved this month, the average time from first CHM meeting to approval would rise to 7.14 - 7.2 months. That would push DCVax-L's likely approval (based on recent averages) into early February. But at that point, there would also be 0 medicines ahead of us in line...

Any clarity would be appreciated. Maybe different versions of the same drug?